This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT05860296
Brief Title: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

First Submitted : April 27, 2023
First Submitted that Met QC Criteria : May 5, 2023
First Posted : May 16, 2023

Last Update Submitted that Met QC Criteria : February 27, 2024
Last Update Posted : February 29, 2024